{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Kymera Therapeutics Announces Key Leadership Appointments - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"90z7Bx0zTR\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-announces-key-leadership-appointments\/\">Kymera Therapeutics Announces Key Leadership Appointments<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-announces-key-leadership-appointments\/embed\/#?secret=90z7Bx0zTR\" width=\"600\" height=\"338\" title=\"&#8220;Kymera Therapeutics Announces Key Leadership Appointments&#8221; &#8212; Market Newsdesk\" data-secret=\"90z7Bx0zTR\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"WATERTOWN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the appointments of William Leong, PhD, as Vice President of Chemistry, Manufacturing and Controls (CMC) and Paul Cox as Vice President of Investor Relations and Communications. \u201cI am excited to welcome both William and Paul to Kymera. These key strategic appointments will significantly strengthen our organizational capabilities as we continue to build Kymera into a fully integrated biotechnology company,\u201d said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics. \u201cAs a rapidly growing organization that is also nearing clinical development, we will benefit from their wealth of experience and proven &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjk4NCMzODgzNzIxIzIyMDA4MzI="}